A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan
ConclusionIn GT1 treatment-na ïve non-cirrhotic patients GLE/PIB was a cost-effective strategy compared to other DAAs. When a pan-genotypic framework was used, the GLE/PIB portfolio dominated the SOF-based portfolio.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Cancer & Oncology | Carcinoma | Cirrhosis | Drugs & Pharmacology | Hepatitis | Hepatitis A | Hepatocellular Carcinoma | Japan Health | Liver Cancer | Study